This document is the curriculum vitae of Julia Balfour, outlining her experience and qualifications as a medical writer and editor based in the UK. She has over 20 years of experience in medical writing for medical publishers, pharmaceutical companies, and as a freelancer. She has authored over 50 publications and provides editorial support and manuscript writing services for research teams. Her areas of expertise include oncology, hematology, nephrology, and health economics.

1. JULIA BALFOUR CV SEP 2015
JULIA ANNE BALFOUR
MEDICAL WRITER/CONSULTANT
Address: 28 Cortachy Crescent, Broughty Ferry, Dundee DD5 3BF, United
Kingdom
Phone +44 1382 731 622 Email: juliabalfour1@btinternet.com
Website: http://www.northstarmedwrite.com/
• UK-based freelance medical writer & editor (Manuscript specialist)
• > 20 years medical writing & technical editing experience (Medical Publishers/ Med
Comms Agencies/ Pharma Industry/ Freelance)
• Proven publishing success: author of > 50 publications, including state of the art
reviews (see appendix for extensive bibliography)
• Extensive experience providing editorial support for leading research teams worldwide
• Specialist ‘Manuscript Doctor’ service offered, as well as abridging & repurposing
• Excellent clinical knowledge (ex-Hospital Pharmacist)
NATIONALITY: Dual Citizenship: British/New Zealand (Native English Speaker)
QUALIFICATION: Bachelor of Science in Pharmacy – Honours, Upper Second Class (Heriot Watt University,
Edinburgh)
MEMBERSHIP: European Medical Writers Association
Therapeutic/Specialist areas
• Oncology (targeted agents and
supportive care)
• Haematology
• Nephrology, Urology
• Endocrinology/metabolism (especially
diabetes), rare diseases
• Infectious diseases
• Experience across all major therapeutic
areas
• Health Economics
Types of projects undertaken
• Primary Manuscripts & Review articles*
• Editing and Publication Support*
• Rewriting (‘Manuscript Doctor’), Abridging,
Repurposing*
• Development of new article types
• Bulletins, Newsletters
• Abstracts, Posters, Slidesets
• Monographs, Dossiers,Textbooks
*see bibliography
1

2. JULIA BALFOUR CV SEP 2015
MEDICAL WRITING CAREER SUMMARY
Title Date Role
Freelance Medical Writer Jul 2007-
continuing
Writing/editing manuscripts with
Research Groups and Pharma
companies; support with publication
process
Principal Medical Writer (Temp contract)
Amgen GmbH, Zug, Switzerland
Feb 2006-Jun 07 Liaising with KOLs to develop and edit
manuscripts and conference abstracts
for 6 Amgen product teams
Freelance Medical Writer Nov 2003-Dec
2005
Various writing projects as required
Editorial Projects Manager (Temp contract)
Adelphi Communications Ltd, Macclesfield, UK
May 2003-Nov
2003
Medical Writer (Temp contract)
Gardiner-Caldwell Communications, Macclesfield, UK
Aug 2002-Apr
2003
Manuscript writing; planning/slide
development for standalone meeting
Freelance Medical Writer Jan 2000-April
2002
Drug reviews; Newsletter reports
Various positions, Adis International, Auckland, New Zealand:
• Senior Medical Writer, Scientific Writing Group
• Managing Editor (Drug Evaluations), Disease
Management & Health Outcomes journal
• Associate Editor/Medical Writer, Scientific Writing
Group
• Associate Managing Editor, Literature Monitoring
Service (LMS)
• Associate Editor, LMS
1988-99
Apr 1993-Dec 1999
Dec 1996-Jun 1998
June 1989-Apr
1993
April 1989-June
1989
May 1988-April
1989
Developing/editing state-of-the art
review manuscripts for Adis/Springer
Journals (Drugs, Pharmacoeconomics,
Drugs in Aging etc);
Technical editing of contributed
manuscripts/conference material;
Managing program of review articles;
Writing reports for Newsletters (e.g.
Inpharma, GP Weekly) and summaries
for LMS;
Custom projects as required
PHARMACY CAREER SUMMARY
• Basic Grade Pharmacist at City Hospital, Edinburgh, Royal Infirmary of Edinburgh and Ninewells Hospital and Medical
School, Dundee, various posts held between 1975 and 1988.
• Locum/temporary work includes Pharmacist/Manager for chain of chemist shops and Staff Pharmacist, Royal Hospital
for Sick Children, Edinburgh.
• Temporary Pharmacist (Section leader), Clinical Trial Supplies, Rorer Health Care (UK) Ltd.
• Pre-Registration Pharmacist, Falkirk Royal Infirmary/City Hospital, Edinburgh.
2

3. JULIA BALFOUR CV SEP 2015
APPENDIX (BIBLIOGRAPHY AND FEEDBACK)
Julia Balfour provided editorial support for the following manuscripts:
Oncology and Supportive Care
EBMT Mucositis Advisory Group
• Blijlevens N, Schwenkglenks M, Bacon P et al. Prospective oral mucositis audit: oral
mucositis in patients receiving high-dose melphalan or BEAM conditioning
chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J
Clin Oncol 2008;26(9): 1519-25.
• Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic
growth factor with multiple biological activities in preventing chemotherapy- and
radiotherapy-induced mucositis. Ann Oncol 2007;18(5): 817-26.
• McCann S, Schwenkglenks M, Bacon P, et al. The Prospective Oral Mucositis Audit:
relationship of severe oral mucositis with clinical and medical resource use outcomes in
patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and
autologous SCT. Bone Marrow Transplant 2009;43(2):141-7.
SAKK Group
• Helbling, D., G. Bodoky, et al. Neoadjuvant chemoradiotherapy with or without
panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a
randomized, multicenter, phase II trial SAKK 41/07. Annals of Oncology 2013; 24(3): 718-
725.
• Koeberle, D., D. C. Betticher, et al. Bevacizumab continuation versus no continuation
after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal
cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology:
official journal of the European Society for Medical Oncology / ESMO 2015; 26(4): 709-714.
German Breast Group
• von Minckwitz G, Kummel S, du Bois A et al. Pegfilgrastim +/- ciprofloxacin for primary
prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for
breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19(2): 292-8.
• Loibl, S., A. Schmidt, et al. (2015). Breast Cancer Diagnosed During Pregnancy: Adapting
Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA oncology. DOI
10.1001/jamaoncol.2015.2413
Other authors
• Pettengell R. Advanced-stage follicular lymphoma in the rituximab era: when should
patients receive anthracycline-based chemotherapy? Drugs 2009;69(13):1727-37.
• Pettengell R, Aapro M, Brusamolino E, et al. Implications of the European Organisation for
Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-
stimulating factor (G-CSF) for lymphoma care. Clin Drug Investig 2009;29(8):491-513.
• Aapro M, Crawford J, Kamioner D: Prophylaxis of chemotherapy-induced febrile
neutropenia with granulocyte colony-stimulating factors: where are we now? Support
Care Cancer 2010;18:529-41
• Pradelli, L., K. Mayer, et al. n-3 fatty acid-enriched parenteral nutrition regimens in elective
surgical and ICU patients: a meta-analysis. Critical Care 2012; 16(5): R184.
• Hitz, F., K. Ribi, et al. Predictors of satisfaction with treatment decision, decision-making
preferences, and main treatment goals in patients with advanced cancer. Support Care
Cancer 2013; 21(11): 3085-3093.
3

4. JULIA BALFOUR CV SEP 2015
• Kunstfeld, R. Smoothened inhibitors in the treatment of advanced basal cell carcinomas.
Curr Opin Oncol 2014; 26(2): 184-195. (editorial)
Haematology
• Newland, A. Romiplostim – A Thrombopoiesis-stimulating Peptibody for the Management
of Chronic Immune Thrombocytopenic Purpura in Adults. Eur Haematol 2008;2(1):48-51.
Available at. http://www.touchoncology.com/articles/romiplostim-thrombopoiesis-
stimulating-peptibody-management-chronic-immune-thrombocytopen-0
• Molineux G, Newland A: Development of romiplostim for the treatment of patients with
chronic immune thrombocytopenia: from bench to bedside. Br J Haematol.
• Stasi R, Newland A, Thornton P, Pabinger I. Should medical treatment options be
exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol.
2010;89(12):1185-95.
• Rodeghiero, F. and M. Ruggeri, Short- and long-term risks of splenectomy for benign
haematological disorders: should we revisit the indications? British Journal of
Haematology, 2012;158(1): 16-29.
• Rodeghiero, F., R. Stasi, et al. (2013). Long-term safety and tolerability of romiplostim in
patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
European Journal of Haematology.
Nephrology
• de Francisco ALM. Medical therapy of secondary hyperparathyroidism in chronic kidney
disease: old and new drugs. Expert Opinion on Pharmacotherapy 2006;7(16): 2215-2224.
• Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia?
Evidence from preclinical studies. Nephrol Dial Transplant 2007;22(7): 1828-39.
• Vervloet M, Bencova V Malberti F, Ashman N, Os I, Saha H, Ureña P, Zitt E, Leavey S, Rix
M, Ryba M, Fouque D, Dehmel B, Wheeler T,Jacobson SH. “Real-World” Use of Cinacalcet
for Managing SHPT in Different European Countries: Analysis of Data from the ECHO
Observational Study. Clin Nephrol, 2010. 74(3): p. 198-208.
• Vervloet, M. G., P. W. du Buf-Vereijken, et al. (2013). Cinacalcet for secondary
hyperparathyroidism: from improved mineral levels to improved mortality? Netherlands
Journal of Medicine 71(7): 348-354.
• Frazao, J. M., J. Braun, et al. (2012). Is serum phosphorus control related to parathyroid
hormone control in dialysis patients with secondary hyperparathyroidism? BMC
Nephrology 13: 76.
• Eller, K. and A. R. Rosenkranz (2012). Editorial: Mast cells: subordinates or masterminds
in autoimmunity? Journal of the American Society of Nephrology : JASN 23(12): 1913-
1914.
• Mann J, Kessler M, Villa G et al. Darbepoetin alfa once every 2 weeks for treatment of
anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol
2007;67(3): 140-8.
• Mikhail, A. and M. Farouk (2013). Epoetin biosimilars in Europe: five years on. Advances
in Therapy 30(1): 28-40.
• Zitt, E., D. Fouque, et al. Serum phosphorus reduction in dialysis patients treated with
cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone
reduction. Clinical Kidney Journal 2013; 6(3): 287-294.
• Hemetsberger, M., R. Oberbauer, et al. EARLIER: an observational study to evaluate the
use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism
in daily clinical practice. Wiener medizinische Wochenschrift 2015; Aug 25. [Epub ahead
of print].
4

5. JULIA BALFOUR CV SEP 2015
Health Economics
• Khellaf, M., et al., Costs of managing severe immune thrombocytopenia in adults: a
retrospective analysis. Ann Hematol, 2011. 90(4): p. 441-6.
• Iannazzo, S., et al., Cost-effectiveness analysis of LHRH agonists in the treatment of
metastatic prostate cancer in Italy. Value in health: the journal of the International Society
for Pharmacoeconomics and Outcomes Research, 2011. 14(1): p. 80-9.
• Eandi, M., L. Pradelli, et al. (2010). Economic evaluation of cinacalcet in the treatment of
secondary hyperparathyroidism in Italy. PharmacoEconomics 28(11): 1041-1054.
• Lee, D., P. Thornton, et al. (2013). Cost effectiveness of romiplostim for the treatment of
chronic immune thrombocytopenia in Ireland. Applied Health Economics and Health
Policy 11(5): 457-469.
• Pradelli, L., et al., Effectiveness and cost-effectiveness of supplemental glutamine
dipeptide in total parenteral nutrition therapy for critically ill patients: a discrete event
simulation model based on Italian data. International Journal of Technology Assessment
in Health Care, 2012. 28(1): p. 22-8.
• Pradelli, L., K. Mayer, et al. (2012). n-3 fatty acid-enriched parenteral nutrition regimens in
elective surgical and ICU patients: a meta-analysis. Critical care 16(5): R184.
• Pradelli, L., M. Eandi, et al. (2013). Cost-effectiveness of omega-3 fatty acid supplements
in parenteral nutrition therapy in hospitals: A discrete event simulation model. Clinical
nutrition.
Laboratory Science (Proteomics)
• Paulitschke, V., C. Gerner, et al. (2014). Proteome profiling of keratinocytes transforming
to malignancy. Electrophoresis. 36(4): 564-576.
• Paulitschke, V., W. Berger, et al. (2015). Vemurafenib Resistance Signature by Proteome
Analysis Offers New Strategies and Rational Therapeutic Concepts. Molecular Cancer
Therapeutics. 14(3); 1-12.
Chronic Prostatitis
• Rees J, Abrahams M, Doble A, Cooper A, Prostatitis Expert Reference Group (PERG).
Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic
pelvic pain syndrome: a consensus guideline. BJU Int. 2015 Feb 24. doi:
10.1111/bju.13101. [Epub ahead of print]
Manuscripts authored/co-authored by Julia Balfour
• Peeters M, Balfour J, Arnold D: Review article: panitumumab - a fully human anti-EGFR
monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol
Ther 2008.
• Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers
predicting clinical outcome of epidermal growth factor receptor-targeted therapy in
metastatic colorectal cancer. J Natl Cancer Inst 2009;101(19):1308-24.
• Balfour JA, Benfield P. Cefpodoxime proxetil. An appraisal of its use in antibacterial
cost-containment programmes, as stepdown and abbreviated therapy in respiratory
tract infections. Pharmacoeconomics 1996;10(2): 164-78.
• Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial
activity, pharmacokinetics and therapeutic efficacy in the treatment of serious
infections. Drugs 1996;51(1): 99-136.
• Balfour JA, Buckley MM. Etodolac. A reappraisal of its pharmacology and therapeutic
5

6. JULIA BALFOUR CV SEP 2015
use in rheumatic diseases and pain states. Drugs 1991;42(2): 274-99.
• Balfour JA, Clissold SP. Bendazac lysine. A review of its pharmacological properties
and therapeutic potential in the management of cataracts. Drugs 1990;39(4): 575-96.
• Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and
pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs
1992;43(2): 259-84.
• Balfour JA, Faulds D. Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in
the treatment of serious infections. Pharmacoeconomics 1993;3(5): 398-421.
• Balfour JA, Faulds D. Repaglinide. Drugs Aging 1998;13(2): 173-80.
• Balfour JA, Figgitt DP. Telithromycin. Drugs 2001;61(6): 815-29; discussion 830-1.
• Balfour JA, Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic
properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs
1991;42(3): 511-39.
• Balfour JA, Goa KL. Dolasetron. A review of its pharmacology and therapeutic potential
in the management of nausea and vomiting induced by chemotherapy, radiotherapy or
surgery. Drugs 1997;54(2): 273-98.
• Balfour JA, Goa KL. Raloxifene. Drugs Aging 1998;12(4): 335-41; discussion 342.
• Balfour JA, Goa KL. Bendamustine. Drugs 2001;61(5): 631-8; discussion 639-40.
• Balfour JA, Goa KL, Perry CM. Alosetron. Drugs 2000;59(3): 511-8; discussion 519-20.
• Balfour JA, Heel RC. Transdermal estradiol. A review of its pharmacodynamic and
pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal
complaints. Drugs 1990;40(4): 561-82.
• Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management
of community-acquired respiratory tract infections. Drugs 2000;59(1): 115-39.
• Balfour JA, McClellan K. Topical eflornithine. Am J Clin Dermatol 2001;2(3): 197-201;
discussion 202.
• Balfour JA, McTavish D. Transdermal estradiol. A review of its pharmacological profile,
and therapeutic potential in the prevention of postmenopausal osteoporosis. Drugs
Aging 1992;2(6): 487-507.
• Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use
in diabetes mellitus. Drugs 1993;46(6): 1025-54.
• Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and
pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990;40(2): 260-
90.
• Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999;57(6): 921-30; discussion 931-2.
• Balfour JA, Todd PA, Peters DH. Fleroxacin. A review of its pharmacology and
therapeutic efficacy in various infections. Drugs 1995;49(5): 794-850.
• Balfour JA, Wilde MI. Dorzolamide. A review of its pharmacology and therapeutic
potential in the management of glaucoma and ocular hypertension. Drugs Aging
1997;10(5): 384-403.
• Balfour JA, Wiseman LR. Moxifloxacin. Drugs 1999;57(3): 363-73; discussion 374.
• Coukell AJ, Balfour JA. Levonorgestrel subdermal implants. A review of contraceptive
efficacy and acceptability. Drugs 1998;55(6): 861-87.
• Davis R, Balfour JA. Terbinafine. A pharmacoeconomic evaluation of its use in
superficial fungal infections. Pharmacoeconomics 1995;8(3): 253-69.
• Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology,
therapeutic efficacy and tolerability. Drugs 1996;51(6): 1019-74.
• Dooley M, Balfour JA. Ibandronate. Drugs 1999;57(1): 101-8; discussion 109-10.
• Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review of its
pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the
chemotherapy of cancer. Drugs 1991;41(3): 400-49.
6

7. JULIA BALFOUR CV SEP 2015
• Foster RH, Balfour JA. Estradiol and dydrogesterone. A review of their combined use as
hormone replacement therapy in postmenopausal women. Drugs Aging 1997;11(4): 309-
32.
• Friedel HA, Balfour JA. Tinzaparin. A review of its pharmacology and clinical potential in
the prevention and treatment of thromboembolic disorders. Drugs 1994;48(4): 638-60.
• Gillies PS, Faulds D, Balfour JA, Perry CM. Ganirelix. Drugs 2000;59(1): 107-11;
discussion 112-3.
• Goa KL, Balfour JA. Risedronate. Drugs Aging 1998;13(1): 83-91; discussion 92.
• Goa KL, Balfour JA, Zuanetti G. Lisinopril. A review of its pharmacology and clinical
efficacy in the early management of acute myocardial infarction. Drugs 1996;52(4): 564-
88.
• Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs 1998;55(6): 813-20; discussion 821-2.
• Langtry HD, Balfour JA. Azithromycin. A review of its use in paediatric infectious
diseases. Drugs 1998;56(2): 273-97.
• Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2
diabetes mellitus. Drugs 1998;55(4): 563-84.
• Lea AP, Bryson HM, Balfour JA. Intracavernous alprostadil. A review of its
pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile
dysfunction. Drugs Aging 1996;8(1): 56-74.
• Lee CR, Balfour JA. Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and
pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain
states. Drugs 1994;48(6): 907-29.
• McClellan KJ, Balfour JA. Eprosartan. Drugs 1998;55(5): 713-8; discussion 719-20.
• Noble S, Balfour JA. Meloxicam. Drugs 1996;51(3): 424-30; discussion 431-32.
• Onrust SV, Lamb HM, Balfour JA. Ofloxacin. A reappraisal of its use in the management
of genitourinary tract infections. Drugs 1998;56(5): 895-928.
• Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999;58(1): 79-88; discussion 89-90.
• Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial
activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral
treatment for acute uncomplicated lower urinary tract infections. Drugs 1997;53(4): 637-
56.
• Perry CM, Balfour JA. Didanosine. An update on its antiviral activity, pharmacokinetic
properties and therapeutic efficacy in the management of HIV disease. Drugs 1996;52(6):
928-62.
• Perry CM, Balfour JA. Fomivirsen. Drugs 1999;57(3): 375-80; discussion 381.
• Peters DC, Balfour JA. Tacalcitol. Drugs 1997;54(2): 265-71; discussion 272.
• Wagstaff AJ, Balfour JA. Combination hepatitis a-hepatitis B vaccine. BioDrugs
1997;8(3): 235-9.
• Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997;53(5): 817-24; discussion 825-7.
• Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability
in combined contraceptive preparations. Drugs 1995;50(2): 364-95.
• Wiseman LR, Balfour JA. Ceftibuten. A review of its antibacterial activity,
pharmacokinetic properties and clinical efficacy. Drugs 1994;47(5): 784-808.
• Wiseman LR, Balfour JA. Ciprofloxacin. A review of its pharmacological profile and
therapeutic use in the elderly. Drugs Aging 1994;4(2): 145-73.
• Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and
clinical potential in the management of open-angle glaucoma and ocular hypertension.
Drugs Aging 1998;12(3): 225-41.
• Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and
therapeutic potential in the management of painful and inflammatory conditions. Drugs
1996;51(4): 639-57.
7

8. JULIA BALFOUR CV SEP 2015
FEEDBACK SAMPLES
[Company X] performance review summary 2006
Julia is widely recognized at [Company X] and by authors and reviewers to be an extremely skilled writer
of manuscripts and review articles. Julia’s writing is of the highest quality and has received comments
from reviewers such as “this is the best written review in this field”. She has an excellent scientific
knowledge and quickly masters a new product/therapeutic area. She very rapidly assimilates new
information and knows how to use it relevantly in her writing. Julia works independently without a lot of
guidance, yet has a good sense of when guidance is needed and appropriately seeks it from team and
authors. She scrutinizes data carefully and does not take things at face value, but rather questions
inconsistencies and thoroughly checks that the data make sense – she adds great value in this capacity
and has detected many errors and flawed analyses that went unnoticed by others. Ensuring quality is
her greatest strength. Julia is very productive; delivering results is also an outstanding strength. She
has also independently driven several projects for the department to help us work faster and smarter.
2. Various emails regarding mucositis review drafted by JB
From Company X
From manager to head office:
We received some really positive comments on the mucositis review that I wanted to share with you.
Julia wrote this and worked directly with the authors through the course of about 4 drafts over 8 months.
As with every piece Julia writes, her superb writing skills receive high praise - her writing makes the
difference between just another review and a high impact publication. I am very proud to have her at
[Company X]!
W
From manager to Julia: On behalf of the [Product Y] team, I’d like to thank you for your truly outstanding
work on this review article. It is rare to achieve the kind of remarks from reviewers that we received on
this paper: Your efforts really made the difference here! It’s great to see it finally in print. W
From Head Office to Julia:
I would like to second W’s comments. I re-read the article this weekend and was very impressed… I am
hoping to find ways in which we can really utilize this manuscript in the future, starting with inclusion as a
pre-read for ad boards.
Thanks for a job well done! B
Peer review comments
Reviewer 1: This is an important and well written review. The data and their interpretation are directly
relevant to clinically significant issues associated with causation and management of mucosal injury in
cancer patients.
Reviewer 2: An excellent review. well-thought out, well-referenced, thorough and timely.
Reviewer 3: This is one of the best written mucositis manuscripts this reviewer has had the opportunity to
review. The presentation of the pathobiology of mucositis is clear, concise, and "state of the arts".
8

9. JULIA BALFOUR CV SEP 2015
3. Linked in endorsement.
"I have worked with Julia, while she was a colleague at [Company Y], but also as a client, when she was
freelancing as a medical writer.
I found Julia to a very reliable colleague, who did wonders writing manuscripts and reviews. Even when
she had been inexperienced with a therapeutic area, she was quickly up to speed with the literature. Her
results proved that she had not only understood, but more importantly brilliantly put the most complex
scientific matter into a comprehensive, easy to read, easy to understand story. I have always enjoyed
reading her work.
I highly recommend Julia as a medical writer, especially for complex pieces like reviews, where excellent
linguistic skills and understanding of complex matters are key."
4. Email from Journal editor to author regarding editorial edited by Julia
Dear Professor X
Thank you for doing this [editorial]--it reads beautifully.
It is a pleasure to receive and publish manuscripts of this quality in JASN. I deeply appreciate your
support of the journal, and we look forward to the opportunity to consider further manuscripts from your
group.
9

10. JULIA BALFOUR CV SEP 2015
3. Linked in endorsement.
"I have worked with Julia, while she was a colleague at [Company Y], but also as a client, when she was
freelancing as a medical writer.
I found Julia to a very reliable colleague, who did wonders writing manuscripts and reviews. Even when
she had been inexperienced with a therapeutic area, she was quickly up to speed with the literature. Her
results proved that she had not only understood, but more importantly brilliantly put the most complex
scientific matter into a comprehensive, easy to read, easy to understand story. I have always enjoyed
reading her work.
I highly recommend Julia as a medical writer, especially for complex pieces like reviews, where excellent
linguistic skills and understanding of complex matters are key."
4. Email from Journal editor to author regarding editorial edited by Julia
Dear Professor X
Thank you for doing this [editorial]--it reads beautifully.
It is a pleasure to receive and publish manuscripts of this quality in JASN. I deeply appreciate your
support of the journal, and we look forward to the opportunity to consider further manuscripts from your
group.
9